QUATTRO-II: A multicenter randomized trial comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Efficacy and safety analysis

被引：0

作者：

Kotaka, M. ^{[1
]}

Bando, H. ^{[2
]}

Satake, H. ^{[3
]}

Kotani, D. ^{[4
]}

Hamaguchi, T. ^{[5
]}

Shiozawa, M. ^{[6
]}

Ikumoto, T. ^{[1
]}

Masuishi, T. ^{[7
]}

Yasui, H. ^{[8
]}

Kagawa, Y. ^{[9
]}

Oki, E. ^{[10
]}

Yamamoto, Y. ^{[11
]}

Kawakami, H. ^{[12
]}

Boku, S. ^{[13
]}

Komatsu, Y. ^{[14
]}

Taniguchi, H. ^{[7
]}

Muro, K. ^{[15
]}

Yamazaki, K. ^{[16
]}

Misumi, T. ^{[17
]}

Yoshino, T. ^{[4
]}

Kato, T. ^{[18
]}

Tsuji, A. ^{[16
]}

机构：

[1] Sano Hosp, Gastrointestinal Canc Ctr, Kobe, Japan

[2] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan

[3] Kochi Med Sch, Dept Med Oncol, Nankoku, Japan

[4] Natl Canc Ctr Hosp East, Kashiwa, Japan

[5] Saitama Med Univ, Int Med Ctr, Hidaka, Japan

[6] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Japan

[7] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Japan

[8] Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Kobe, Japan

[9] Osaka Gen Med Ctr, Dept Gastroenterol Surg, Osaka, Japan

[10] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan

[11] Univ Tsukuba, Dept Gastroenterol, Fac Med, Tsukuba, Japan

[12] Kindai Univ, Fac Med, Osakasayama, Japan

[13] Kansai Med Univ, Hirakata, Japan

[14] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Japan

[15] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan

[16] Shizuoka Canc Ctr, Dept Gastrointestinal Oncol, Shizuoka, Japan

[17] Natl Canc Ctr Hosp East, Dept Data Sci, Kashiwa, Japan

[18] Osaka Natl Hosp, Natl Hosp Org, Dept Surg, Osaka, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.04.205

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-149

引用

页码：S68 / S68

页数：1

共 50 条

[41] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study
Antonuzzo, Lorenzo
Giommoni, Elisa
Pastorelli, Davide
Latiano, Tiziana
Pavese, Ida
Azzarello, Domenico
Aieta, Michele
Pastina, Ilaria
Di Fabio, Francesca
Bertolini, Alessandro
Corsi, Domenico Cristiano
Mogavero, Selene
Angelini, Valentina
Pazzagli, Mario
Di Costanzo, Francesco
WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (23) : 7281 - 7288
[42] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer:The OBELIX study
Lorenzo Antonuzzo
Elisa Giommoni
Davide Pastorelli
Tiziana Latiano
Ida Pavese
Domenico Azzarello
Michele Aieta
Ilaria Pastina
Francesca Di Fabio
Alessandro Bertolini
Domenico Cristiano Corsi
Selene Mogavero
Valentina Angelini
Mario Pazzagli
Francesco Di Costanzo
World Journal of Gastroenterology, 2015, (23) : 7281 - 7288
[43] Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer Analysis of Multiple Methods
Li, Shaotang
Chi, Pan
BIODRUGS, 2011, 25 (01) : 43 - 50
[44] The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
Tsuji, Akihito
Ohori, Hisatsugu
Yamaguchi, Tatsuro
Matsuura, Masato
Nishioka, Atsujiro
Makiyama, Akitaka
Noura, Shingo
Kochi, Mitsugu
Sagawa, Tamotsu
Kotaka, Masahito
Kubota, Yutaro
Sunakawa, Yu
Sekikawa, Takashi
Nakamura, Masato
Takeuchi, Masahiro
Ichikawa, Wataru
Fujii, Masashi
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[45] Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study
Kotani, Daisuke
Yoshino, Takayuki
Kotaka, Masahito
Kawazoe, Akihito
Masuishi, Toshiki
Taniguchi, Hiroya
Yamazaki, Kentaro
Yamanaka, Takeharu
Oki, Eiji
Muro, Kei
Komatsu, Yoshito
Bando, Hideaki
Satake, Hironaga
Kato, Takeshi
Tsuji, Akihito
INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1649 - 1655
[46] FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
Antoniotti, Carlotta
Vetere, Guglielmo
Cremolini, Chiara
ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (18)
[47] Safety analysis of first-line bevacizumab plus chemotherapy in patients with metastatic colorectal cancer (mCRC) participating in a US registry
Kozloff, M.
Cohn, A.
Christiansen, N.
Flynn, P.
Kabbinavar, F.
Robles, R.
Ulcickas-Yood, M.
Sarkar, S.
Hambleton, J.
Grothey, A.
EJC SUPPLEMENTS, 2005, 3 (02): : 173 - 173
[48] Efficacy and safety of surgery with curative intent in patients treated with first-line Bevacizumab plus chemotherapy for metastatic colorectal cancer: First beat
Kretzschmar, A.
Cunningham, D.
Berry, S.
Rivera, F.
Di Bartolomeo, M.
Mazier, M.
Van Cutsem, E.
ANNALS OF ONCOLOGY, 2008, 19 : I25 - I25
[49] A comparison of efficacy of first-line chemotherapy regimens for metastatic colorectal cancer (mCRC): FOLFIRI plus bevacizumab vs. XELIRI plus bevacizumab
Ocvirk, J.
Rebersek, M.
Boc, M.
EJC SUPPLEMENTS, 2009, 7 (02): : 336 - 336
[50] Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer
Sledge, G.
Miller, K.
Moisa, C.
Gradishar, W.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

← 1 2 3 4 5 →